MARKET

MTNB

MTNB

Matinas
AMEX

Real-time Quotes | Nasdaq Last Sale

0.9200
+0.0059
+0.65%
Closed 18:35 06/16 EDT
OPEN
0.9101
PREV CLOSE
0.9141
HIGH
0.9449
LOW
0.8911
VOLUME
2.27M
TURNOVER
--
52 WEEK HIGH
2.220
52 WEEK LOW
0.6610
MARKET CAP
187.94M
P/E (TTM)
-7.7966
1D
5D
1M
3M
1Y
5Y
Return On Capital Employed Overview: Matinas BioPharma Hldgs
Matinas BioPharma Hldgs (AMEX:MTNB) reported Q1 sales of $33.33 thousand. Earnings fell to a loss of $6.35 million, resulting in a 2.09% decrease from last quarter. In Q4, Matinas BioPharma Hldgs brought in $62.50 thousand in sales but lost $6.49 million i...
Benzinga · 06/07 14:00
Matinas BioPharma to Hold Virtual R&D Day on June 17, 2021
Matinas will highlight progress across its lipid nanocrystal (LNC) delivery platform and associated pipeline programs
GlobeNewswire · 05/20 12:00
--Piper Sandler Cuts Matinas BioPharma Holdings to Neutral From Overweight, Price Target to $0.90 From $4
MT Newswires · 05/11 11:14
Matinas BioPharma (MTNB) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Matinas BioPharma (MTNB) today and set a price target of $3.00. The company's shares closed
SmarterAnalyst · 05/11 10:26
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates
Zacks.com · 05/10 11:45
Matinas Biopharma EPS and revenue in-line
Matinas Biopharma (MTNB): Q1 GAAP EPS of -$0.03 in-line.Revenue of $0.03M in-line.Cash, cash equivalents and marketable securities of ~ $60.7M.Based on current projections, the Company believes that cash on hand
Seekingalpha · 05/10 10:40
Matinas BioPharma Hldgs Q1 EPS $(0.03), Inline, Sales $33.33K Beat $20.00K Estimate
Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of
Benzinga · 05/10 10:32
10-Q: MATINAS BIOPHARMA HOLDINGS, INC.
(EDGAR Online via COMTEX) -- Note 2 - Liquidity and Plan of Operations The Company has experienced net losses and negative cash flows from operations each...
Edgar Online - (EDG = 10Q, 10K) · 05/10 10:32
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MTNB. Analyze the recent business situations of Matinas through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MTNB stock price target is 2.567 with a high estimate of 3.500 and a low estimate of 0.9000.
EPS
Institutional Holdings
Institutions: 50
Institutional Holdings: 32.50M
% Owned: 15.91%
Shares Outstanding: 204.28M
TypeInstitutionsShares
Increased
8
1.69M
New
5
268.22K
Decreased
14
4.48M
Sold Out
11
2.85M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.64%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
Chairman/Independent Director
Herbert Conrad
President/Chief Executive Officer/Director
Jerome Jabbour
Vice Chairman/Independent Director
Patrick LePore
Chief Financial Officer
Keith Kucinski
Chief Technology Officer
Hui Liu
Chief Scientific Officer
Raphael Mannino
Other
James Ferguson
Other
Theresa Matkovits
Independent Director
Eric Ende
Independent Director
Natasha Giordano
Independent Director
Matt Wikler
Independent Director
James Scibetta
Independent Director
Matthew Wikler
No Data
About MTNB
Matinas BioPharma Holdings, Inc., is a development stage biopharmaceutical company. The Company focuses on identifying and developing novel pharmaceutical products. The Company's technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, which is designed to make safer, more tolerable, less toxic and orally bioavailable. The Company's technology combines the use of lipids as active pharmaceutical ingredients (APIs) and the use of lipids in cochleate-shaped lipid-crystal nano-particle drug delivery vehicles. The Company’s product candidates include, MAT2203 and MAT2501.The Company's anti-infective product candidate, MAT 2203, is an application of its cochleate delivery technology to a spectrum anti-fungal drug called amphotericin B. The Company's MAT2501 is an orally administered, encochleated formulation of the spectrum IV-only aminoglycoside antibiotic agent amikacin, utilizes the Company's lipid-crystal, nanoparticle delivery technology.

Webull offers kinds of Matinas BioPharma Holdings Inc stock information, including AMEX:MTNB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTNB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MTNB stock methods without spending real money on the virtual paper trading platform.